Monday, May 21, 2018
Company News: Page (1) of 1 - 02/14/18 Email this story to a friend. email article Print this page (Article printing at page facebook
Veloxis Secures USD 60M in Debt Financing

(February 14, 2018)

Company Release no. 01/2018


To: NASDAQ Copenhagen A/S                                                       14 February 2018


Veloxis Secures USD 60M in Debt Financing


Cary, NC, February 14, 2018 -- Veloxis Pharmaceuticals A/S (OMX:VELO), a specialty pharmaceutical company committed to improving the lives of transplant patients, today announced that it has obtained USD 60 million of capital from funds managed by Athyrium Capital Management, LP (“Athyrium”), a leading healthcare-focused investment firm. The proceeds from the commitment will be used to refinance Veloxis’s outstanding debt, accelerate the growth of Envarsus XR in the U.S. and help fund working capital of Veloxis Pharmaceuticals, Inc.

“We are pleased to have this opportunity to collaborate with Athyrium, a partner known for its strategic investments in healthcare. The USD 60 million non-dilutive financing enhances our cash position and provides the Company with the capital needed to execute on our commercial strategy with Envarsus. Athyrium is also committed to being a long-term partner for the Company to help fund future business development opportunities which we believe will maximize long term shareholder value,” said Craig Collard, President and Chief Executive Officer of Veloxis. 

Richard Pines, Partner at Athyrium, stated: “We are excited about funding the commercial launch of Envarsus XR. Its strong traction in a genericized market is an indication of the strength of its clinical profile, as transplant surgeons and nephrologists seek to best manage transplant rejection and immunosuppression in this fragile patient population. In addition to our interest in Envarsus XR, we are very impressed with the Veloxis management team and look forward to partnering with them as they seek to grow through business development initiatives.”


Transaction Terms

This financing is in the form of a five-year, floating rate, interest only note. The initial principal balance doubles the amount of debt at substantially the same cost of capital versus the previous debt instrument. The funds are structured with USD 60 million available immediately upon closing of the transaction to Veloxis Pharmaceuticals, Inc., and guaranteed by Veloxis Pharmaceuticals A/S.


For more information, please contact:

Craig A. Collard
President & CEO          
Phone: +1 919 591 3090         
Email: [email protected]


About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a biopharmaceutical company focused on improving patient lives by identifying, developing, and commercializing meaningful products in transplantation and adjacent therapies. Utilizing our proprietary drug delivery technology (MeltDose®), Veloxis has developed and obtained FDA and EMA approval for our product, Envarsus XR (tacrolimus extended-release tablets), to aid in the prophylaxis of organ rejection in transplant recipients.  Our strategy is to continue to commercialize Envarsus XR in the U.S. with a direct salesforce and to license rights to Envarsus to proven commercial partners in other territories around the world.  In addition to expanding use of Envarsus, Veloxis is actively seeking business development and licensing targets within the areas of transplantation and adjacent specialties, and therapeutics for rare or severe disease for which chronic therapy is initiated in the large hospital setting.  Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit


About Athyrium Capital Management

Athyrium Capital Management, LP, is a specialized asset management company that invests in the global healthcare sector. As of December 31, 2017, Athyrium had approximately $3.5 billion of assets under management. The Athyrium team has substantial investment experience in the healthcare sector across a wide range of asset classes including public equity, private equity, fixed income, royalties, and other structured securities. Athyrium invests across all healthcare verticals, including biopharma, medical devices and products, and healthcare focused services. The Athyrium team partners with management teams to implement creative financing solutions to companies’ capital needs. For more information, please visit

Page: 1

Related Keywords:
Related Sites: DMN Newswire , ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter

  • Sanofi: Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
  • Global Molecular Diagnostics Markets, 2016-2024 - Focus on Infectious Disease Testing, Blood Screening, Cancer Screening & Other Applications
  • Global Sleep Apnea Diagnostic and Therapeutic Devices Strategic Business Report 2018
  • Global Sleep Apnea Diagnostic and Therapeutic Devices: 2016/18-2024 Strategic Business Analysis & Forecast Report - mHealth-Enabled Sleep Tracking Devices Gain Ground
  • Blavatnik Family Foundation Provides $10 Million Gift to Mount Sinai to Support Mission of Advancing Women’s Health

  • Oasmia Pharmaceutical Completes Spin-off of Veterinary Oncology Assets to Wholly Owned US Subsidiary, AdvaVet, Inc.
  • HedgePath Pharmaceuticals Announces Additional Expanded Patent Coverage
  • Dr. Haydee Gonzalez Hidalgo joins The Oncology Institute of Hope and Innovation
  • eClinical Solutions Market Size Is Projected To Reach $13 Billion By 2024
  • Multiple New Vendor GPO Awards Position Keneric Healthcare to Increase Its Market Reach for Their Advanced Wound Care and Patient Cleansing Products Lines

    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines